Amarin and Multicell Sign Exclusive Licence Agreement for MS Fatigue Treatment
By Business Review Editor
Pharma Deals Review: Vol 2006 Issue 68 (Table of Contents)
Published: 6 Feb-2006
DOI: 10.3833/pdr.v2006.i68.562 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Multicell entered into license agreement with Amarin to obtain exclusive worldwide rights for Amarin’s LAX-202 for treating fatigue in patients suffering from multiple sclerosis...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS